Trial Profile

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Guselkumab (Primary) ; Golimumab
Indications Psoriatic arthritis
Focus Therapeutic Use
Acronyms EVOLUTION

Most Recent Events

19 Mar 2025 Trial design published in the Trials
29 Aug 2024 Planned number of patients changed from 300 to 150.
03 Jun 2023 Status changed to recruiting, as per results presented at the 24th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com